Sweden to invest $320 million in life sciences

Wednesday, September 12, 2012 10:41 AM

A delegation of four ministers from the Swedish government, led by the Prime Minister Fredrik Reinfeldt, confirmed the country's largest ever investment in life sciences as a key element of the ruling coalition's autumn budget and research and innovation bill.

Roughly $320 million of the $1.7 billion package will be devoted to the life sciences over the next four years. The package includes a $220 million investment in drug discovery, clinical research, antibiotic resistance research, health in aging and the use of patient registers 

The package also includes a $100 million investment in SciLifeLab, a center combining state-of-the-art research infrastructure with a broad knowledge in translational medicine and molecular bioscience in order to translate discoveries into both tools and therapies. This investment more than doubles the government's current funding of SciLifeLab. 

The majority of the life science investments will be in Stockholm-Uppsala region, already home to more than 50% of Sweden's thriving life science industry.

"In our recently published report, we pointed out the ambitious, future plans for further strengthening the life science sector in Stockholm-Uppsala, thereby ensuring that the region remains a truly global life science cluster,” said Ola Bjorkman, CEO of Stockholm-Uppsala Life Sciences. “In particular, the investment in SciLifeLab with its cutting edge research infrastructure combined with parallel investments in drug discovery, clinical research and the use of patient registers open new avenues for developing more personalized and outcome orientated healthcare." 

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs